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a  b  s  t  r  a  c  t
Glycosylation  is  one  of the most  common  and  important  post-translational  modiﬁcations,  inﬂuencing
both  the chemical  and  the  biological  properties  of  proteins.  Studying  the  glycosylation  of the  entire  pro-
tein  population  of  a sample  can  be  challenging  because  variations  in  the  concentrations  of  certain  proteins
can  enhance  or obscure  changes  in  glycosylation.  Furthermore,  alterations  in  the  glycosylation  pattern
of  individual  proteins,  exhibiting  larger  variability  in disease  states,  have  been  suggested  as  biomark-
ers  for  different  types  of  cancer,  as well  as inﬂammatory  and  neurodegenerative  diseases.  In  this  paper,
we  present  a rapid  and  efﬁcient  method  for glycosylation  analysis  of  individual  proteins  focusing  on
changes  in  the  degree  of fucosylation  or other alterations  to  the  core  structure  of  the glycans,  such  as
the  presence  of bisecting  N-acetylglucosamines  and  a  modiﬁed  degree  of branching.  Streptavidin-coated
magnetic  beads  are  used  in combination  with  genetically  engineered  immunoafﬁnity  binders,  called  VHH
antibody  fragments.  A  major  advantage  of the  VHHs  is  that  they  are  nonglycosylated;  thus,  enzymatic
release  of  glycans  from  the  targeted  protein  can  be  performed  directly  on  the beads.  After  deglycosyla-
tion,  the  glycans  are  analyzed  by  MALDI-TOF-MS.  The  developed  method  was  evaluated  concerning  its
speciﬁcity,  and  thereafter  implemented  for studying  the glycosylation  pattern  of  two  different  proteins,
alpha-1-antitrypsin  and  transferrin,  in  human  serum  and  cerebrospinal  ﬂuid.  To our  knowledge,  this  is
the  ﬁrst  example  of a  protein  array-type  experiment  that  employs  bead-based  immunoafﬁnity  puriﬁca-
tion  in combination  with  mass  spectrometry  analysis  for fast  and  efﬁcient  glycan  analysis  of  individual
proteins  in biological  ﬂuid.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
N-linked glycosylation is one of the most common post-
ranslational modiﬁcations of proteins. The processes that
lycosylate proteins are enzyme driven and can be affected by sev-
ral factors, such as pregnancy, diet, alcohol abuse, or different
iseases. A speciﬁc protein will in many cases retain its glycosy-
ation after leaving the cell where it was produced. This implies
hat information concerning the state of the cell where the protein
as produced could be gathered by sampling proteins far from the
ell of origin [1]. Our knowledge of the changes to protein glycosy-
ation as a consequence of disease has increased substantially over
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731-7085/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
the last decade [1–5]. Many of the serum protein biomarkers that
are used to detect or monitor cancer are glycoproteins and several
changes to protein glycosylation have also been presented [1,6].
For example, the presence of bisecting N-acetylglucosamine (Glc-
NAc) and increased fucosylation of the antennae of glycans have
been shown to correlate with different cancer types. Changes to
the glycosylation of immunoglobulin- [7], alpha-1-acid glycopro-
tein [8] and alpha-1-antitrypsin (AAT) [5], among others, have been
observed for inﬂammatory diseases. Change in glycosylation has
also been observed in several neurodegenerative diseases, but in
these conditions, cerebrospinal ﬂuid (CSF), rather than serum, is
the biological sample of choice [3,9–12]. The rationale for this is
that so-called brain-type glycosylation occurs in proteins native to
the central nervous system [13–15]. Such brain-type glycosylation
is characterized by high levels of bisecting GlcNAc and proximal
fucosylation.
Bead-based approaches for the selective extraction of a
single protein from a complex biological sample have been
used extensively for studies concerning protein complexes or
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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nteractions between proteins [16,17]. However, bead-based
pproaches have found limited use in the study of protein gly-
osylation. Most studies concerning the glycosylation of speciﬁc
roteins have been performed using a combination of one- or two-
imensional gel-electrophoretic separation of proteins followed by
nzymatic release of the glycans from excised spots [12,18,19].
ead-based protocols can more easily be multiplexed and run
n parallel than two-dimensional gel electrophoresis and have a
igher degree of selectivity than one-dimensional gel electrophore-
is. Currently, the most efﬁcient methods for glycan pattern analysis
f speciﬁc proteins use bead-based afﬁnity extraction in combi-
ation with ﬂuorescent labeling of enzymatically released glycans
nd subsequent separation and detection using multichannel cap-
llary electrophoresis with laser-induced ﬂuorescence detection
20]. This combination has been used to evaluate immunoglobu-
in A and AAT as possible biomarkers using 2415 different serum
amples. Although ﬂuorescence detection is a very good quantita-
ive technique, it does not have the possibility of providing any
dditional data concerning the chemical structure of the glycan
ther than the elution or migration time in the chromatographic
r electrophoretic separation system.
We  have developed a method for glycan analysis of selected
erum and CSF proteins using afﬁnity binders immobilized on
articles. Streptavidin-coupled magnetic microparticles were used
or the immobilization of genetically engineered immunoafﬁnity
inders. The captured proteins were then deglycosylated using
eptide N-glycosidase F (PNGase-F) and desialylated using neu-
aminidase directly on the beads. Removing the sialic acids reduces
he heterogeneity of the glycans that may  arise from different
egrees of sialylation, highlighting the differences corresponding
o alterations to the glycan core structures. A simple clean-up and
esalting step using spin-tips containing a carbon particulate phase
ere employed for sample preparation of the released glycans prior
o MALDI-MS analysis.
. Experimental
.1. Materials and reagents
PierceTM streptavidin magnetic beads, HypersepTM
orous graphitized carbon (hypercarb) spin tips 10–200 L,
aptureSelectTM Biotin anti-AAT conjugate, and CaptureSelectTM
iotin anti-transferrin conjugate were obtained from Thermo
cientiﬁc (Waltham, MA,  USA). Standard human AAT was  obtained
rom Acris Antibodies Inc. (San Diego, CA, USA). Amicon Ultra
.5-mL centrifugal ﬁlters, 2,5-dihydroxybenzoic acid (DHB),
imethylaniline (DMA), standard human transferrin, and the
ommercially available N-linked glycan standards H5N2 [(Gal-
lcNac)2Man3(GlcNac)2] and H5N4 [2Man3(GlcNac)2] were
urchased from Sigma-Aldrich (St. Louis, MO,  USA). PNGase F
it for enzymatic release of N-linked glycans and -2-3,6,8 neu-
aminidase kit for the release of sialic acids were obtained from
ew England Biolabs UK Ltd. (Hitchin, UK). Acetonitrile (analytical
rade) was purchased from Rathburn Chemicals Ltd. (Walkerburn,
K). Water was puriﬁed using a Millipore water puriﬁcation
ystem to resistance >18 M/cm.
.2. Biological samples
.2.1. Human serum sample
Reference human blood samples were acquired from healthyonors through Karolinska Institutet, Sweden. Once received, the
amples were centrifuged at 1100 × g for 15 min  and the clear
erum aliquoted into microtubes and stored at −80◦ C until further
se.and Biomedical Analysis 132 (2017) 125–132
2.2.2. Human CSF sample
Neurologically healthy control CSF samples were obtained from
the study conducted by Kamali-Moghaddam et al. [21]. That
study, which was  conducted in accordance with the Declaration
of Helsinki, was approved by the Regional Ethical Review Boards of
Uppsala, Sweden and Cluj, Romania, respectively, and the written
consent of the individual donors were obtained.
2.3. General procedure for immunoprecipitation using magnetic
beads and VHH antibody fragments
Aliquots of streptavidin-coated magnetic bead suspensions
(50 L, 10 mg/mL) were transferred to 0.5-mL tubes. By using a
magnet to sediment the particles, the supernatant (storage liquid)
was discharged and the beads were washed with phosphate-
buffered saline (PBS) (3 × 300 L). After washing, a solution of
AAT/transferrin CaptureSelectTM camelid single domain antibody
fragments (VHHs) in PBS (150 L, 0.0167 mg/mL) was added to
the magnetic beads, followed by incubation for 1 h at room tem-
perature while mixing, to facilitate biotin–streptavidin binding.
Thereafter, the magnetic beads were washed with PBS (3 × 300 L)
and incubated with sample solution (150 L) for 1 h at room tem-
perature while mixing, to allow the protein to be captured by
the VHH antibody fragment. Optimization of the protein-binding
time was  performed by following the reaction with capillary elec-
trophoresis (CE) for 2 h. During this time, small aliquots (7 L) of
the supernatant were withdrawn after 0, 5, and 30 min, and 1, 1.5,
and 2.0 h.
After protein binding, the supernatant was discarded and the
magnetic beads were washed with PBS (2 × 300 L). Samples from
the washing steps were saved for CE analysis. To avoid a contri-
bution by nonspeciﬁcally bound proteins adsorbed to the plastic,
a third aliquot of PBS (150 L) was  used to suspend the beads and
transfer them to clean 0.5-mL tubes, followed by a fourth wash with
PBS (150 L). Enzymatic cleavage of the glycans from the bead-
immobilized proteins was conducted using a mixture of PNGase F
and neuraminidase (5:1 U) in H2O (total volume 150 L). Release of
glycans was achieved after 2 h of incubation while mixing at 37 ◦C.
For comparison, deglycosylation was  also performed for 4 and 18 h.
The supernatant containing the glycans was subsequently col-
lected and puriﬁed using porous graphitized carbon solid-phase
extraction spin tips, in accordance with the manufacturer’s instruc-
tions. Activation of the columns was  performed by adding 0.05%
TFA in ACN/H2O (6:4) (3 × 50 L) followed by 0.05% TFA in H2O
(3 × 50 L). The glycan-containing supernatant was  then loaded
on the carbon and the column was washed with 0.05% TFA in
H2O (3 × 50 L). Finally, the glycans were eluted with 0.05% TFA
in ACN/H2O (6:4) (4 × 50 L). Before mass spectrometry analysis,
the sample was  concentrated to approximately 5 L by solvent
evaporation at room temperature using a stream of N2. After con-
centration, the sample was mixed 1:1 v/v with the matrix solution
(DHB/DMA; 21.52 mg/ml  DHB and 4.64 mg/ml  DMA  in 50% ACN)
and spotted (1 L) on a MALDI plate.
2.3.1. Standard AAT protein
Standard AAT protein (0.051 mg/mL) in PBS was used as a pos-
itive control for AAT CaptureSelectTM VHH in the development of
the optimized general procedure for immunoprecipitation using
magnetic beads and VHH antibody fragments.
2.3.2. Standard transferrin protein
Standard transferrin protein (0.13 mg/mL) in PBS was  used
as a positive control for transferrin CaptureSelectTM VHH in the
development of the optimized general procedure for immunopre-
cipitation using magnetic beads and VHH antibody fragments.
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.3.3. Protein mix A
Protein mix  A was prepared by mixing AAT (0.040 mg/mL),
uman serum albumin (0.70 mg/mL), transferrin (0.098 mg/mL),
nd herceptin (0.31 mg/mL) in PBS. This mix  was  used as a posi-
ive control for both AAT and transferrin CaptureSelectTM VHHs in
he development of the optimized general procedure for immuno-
recipitation using magnetic beads and VHH antibody fragments.
.3.4. Protein mix B
Protein mix  B was prepared by mixing ceruloplasmin
0.037 mg/mL), human serum albumin (0.70 mg/mL), transferrin
0.098 mg/mL), and herceptin (0.31 mg/mL) in PBS. This mix  was
sed as a negative control for the AAT CaptureSelectTM VHH in the
evelopment of the optimized general procedure for immunopre-
ipitation using magnetic beads and VHH antibody fragments.
.3.5. Protein mix C
Protein mix  C was prepared by mixing AAT (0.040 mg/mL), ceru-
oplasmin (0.027 mg/mL), human serum albumin (0.70 mg/mL),
nd herceptin (0.31 mg/mL) in PBS. This mix  was used as a negative
ontrol for the transferrin CaptureSelectTM VHH in the develop-
ent of the optimized general procedure for immunoprecipitation
sing magnetic beads and VHH antibody fragments.
.3.6. Human serum
Human serum was diluted approximately 20 times with PBS
efore addition to the magnetic beads coated with either AAT or
ransferrin CaptureSelectTM VHH antibody fragments.
.3.7. Human CSF
To establish the same binding conditions as for serum, the
uman CSF was preconcentrated approximately 20 times using
micon centrifugal ﬁlters followed by 20-fold dilution with PBS
efore addition to the magnetic beads coated with either AAT or
ransferrin CaptureSelectTM VHH antibody fragments. This step also
unctions as a clean-up removing salts as well as peptides and small
roteins.
.4. MALDI-TOF-MS analysis
All of the mass spectra were acquired using a Voyager-DETM
TR mass spectrometer (PerSeptive Biosystems, Framingham, MA,
SA), equipped with a nitrogen laser (337 nm), in reﬂector mode
nd with positive ionization. Before each analysis, the instru-
ent was calibrated using a mixture of the Man5 and NA2 glycan
tandards. The acquisition was performed with an accelerating
otential of 20 kV, grid voltage set at 60%, and a delay time of 100 ns.
he laser intensity was set at the lowest value that could produce
trong glycan peaks while keeping the noise level low. Spectra were
cquired in the mass range from m/z  800 to m/z  3000, with the Low
ass Gate set at m/z 700. All spectra, resolutions, and signal-to-
oise ratios were processed and calculated using the Data Explorer
4 software (Applied Biosystems Inc., Foster City, CA, USA).
.5. Capillary electrophoresis analysis
To determine the yield of the immunoafﬁnity extraction of
he target proteins, a previously published CE method [16] was
dapted and modiﬁed on a Hewlett Packard 3D CE instrument
quipped with a UV/Vis diode array detector. The separation was
arried out with a 0.1 M borate buffer (pH 10) as a background
lectrolyte in a fused silica capillary (effective length 80 cm,  i.d.
0 m),  using a positive voltage of 30 kV at room temperature.
his resulted in a separation current of 75 A. The samples were
njected hydrokinetically by applying pressure of 30 mbar for 30 s.
he detection of the target proteins was performed at 200 nm,  withand Biomedical Analysis 132 (2017) 125–132 127
a 20-nm bandwidth. To each sample 3 L of a solution containing
295 mM sodium hydrogen carbonate and 1.3 mM sodium benzoate
(volumetric internal standard) was  added. When transferrin was
analyzed this solution also contained 4.0 mM iron(III)chloride to
induce all transferrin molecules to adopt the same charge state.
Samples were further diluted to a ﬁnal volume of 10 L by the addi-
tion of deionized water. This gave ﬁnal concentrations in the sample
solution of 88, 1.2, and 0.4 mM respectively for sodium hydrogen
carbonate, iron(III)chloride, and sodium benzoate respectively. The
total length of the run under these conditions was 35 min, including
the conditioning of the capillary.
3. Results and discussion
For developing the present method, streptavidin-coated mag-
netic microbeads were used. At an early stage, these particles were
compared with N-hydroxysuccinimide-activated agarose beads for
use as the afﬁnity capture media, but nonspeciﬁc interaction of
proteins with the agarose beads was more prevalent. The mag-
netic beads also have the advantage of being easy to handle using
magnets. Commercially available VHH antibody fragments were
used for both AAT and transferrin. The most common afﬁnity
reagent, immunoglobulin- (IgG), typically consists of two  iden-
tical heavy (H) peptide chains and two  identical light (L) peptide
chains consisting of four and two  domains respectively [22]. VHH
antibody fragments are the single variable domains derived from
homodimeric heavy-chain antibodies (HCAabs), originally found
in Camelidae [23]. As these genetically engineered constructs are
equivalent to one Fab domain in a conventional antibody, they are
antigen-binding fragments. In addition to their small size (approx-
imately 15 kDa), other properties such as a long shelf-life [24] and
structural stability under harsh chemical and thermal conditions
[25] make them a powerful tool for various diagnostic and thera-
peutic applications. Nonglycosylated binders have the advantage of
facilitating the direct on-bead deglycosylation of captured proteins,
thus simplifying the workﬂow and shortening the overall time of
the procedure.
The initial tests of the afﬁnity capture and enzymatic release
steps were performed with volumes and reagents as suggested by
the supplier. Miniaturization of the reactions was then performed
to reduce the consumption of reagents and afﬁnity binders. This
also shortens the overall reaction time by eliminating or reducing
evaporation steps prior to the MALDI sample preparation. The total
time required for the full assay, including the MALDI-MS experi-
ment, was 6 h. A schematic overview of the full procedure can be
seen in Fig. 1.
3.1. Selection of target proteins
The rationale for choosing AAT and transferrin as target proteins
in the development and assessment of this method is that both of
these proteins have the potential to be used as glycan biomarkers.
AAT is a protease inhibitor of approximately 52 kDa that can be gly-
cosylated at three different sites and its concentration in plasma
can ﬂuctuate from 0.88 to 1.68 mg/mL, increasing three to four
times during inﬂammatory and malignant conditions. Additionally,
changes in the glycosylation pattern of this protein have been asso-
ciated with cardiovascular and metabolic diseases, as well as liver
malfunction [20]. Transferrin is a protein of approximately 80 kDa
with a plasma concentration of 2–3 mg/mL. It is composed of 679
amino acids arranged into two domains, each of which contains an
iron-binding site. The main function of transferrin is binding Fe3+
and transporting it through the body as a way of regulating the iron
concentration in biological ﬂuids. Glycosylation can occur at two
different sites of the protein and the glycosylation state of trans-
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errin has been used to diagnose chronic alcoholism and congenital
isorders of glycosylation, among others [26,27].
.2. Assessment of binding efﬁciency using CE
The time required for performing an assay depends on the pro-
ein and reagent concentrations and the strength of the interaction
etween the binder used and the target protein. A higher equi-
ibrium binding constant facilitates shorter reaction times. The
apture efﬁciency of the protein by the immunoafﬁnity reagent was
tudied using CE. CE was chosen because of the small injection vol-
mes necessary for this technique, whereby the supernatant and
ash solution were sampled on several occasions in the workﬂow
ithout signiﬁcant losses. Quantiﬁcation of AAT and transferrin
as performed using a solvent-matched calibration curve ranging
rom 0.08 to 0.28 mg/mL. The amounts of protein used correspond
o the amounts present in diluted serum and are at approximately
ig. 2. Glycan species detected and their (a) average intensity and (b) normalized area afte
s  the area for a speciﬁc glycan signal (for instance m/z = 1810) divided by the sum of th
rom  two replicates analyzed in duplicate. Error bars indicate standard deviations. glycosylation analysis of individual proteins in biological ﬂuids.
two to three times in excess compared with the amount of VHH
used. Triplicate analysis of the supernatant of the binding step,
withdrawn at speciﬁc times as mentioned above, showed that the
binding of both AAT and transferrin was completed in the ﬁrst
10 min  of the incubation. After this time point, the concentration
of both proteins in the supernatants remained stable (Supporting
information, Fig. S1), indicating saturation of the VHHs by the target
protein. Moreover, the analyses of the supernatant in the subse-
quent washing step showed that no detectable amounts of protein
were released, proving the effectiveness of the binding (results not
shown).
3.3. Assessment of deglycosylation efﬁciencyThe deglycosylation efﬁciency of the employed enzyme mixture
(PNGase F and neuraminidase 5:1 U) was  followed over time. The
bead-based procedure described above was used to capture AAT
r different deglycosylation times for AAT standard. The normalized area is calculated
e areas from all the glycan signals in that spectrum. Mean values were generated
utical and Biomedical Analysis 132 (2017) 125–132 129
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Table 1
Identiﬁcation of the different glycan species.
*Composition residues of glycans: H, hexose; N, N-acetylglucosamine; F, fucose
*Structure composition: blue circles, N-acetylglucosamine; green circles, mannose;
yellow circles, galactose; orange triangles, fucose
Peak [M + Na]+ Identity Structure
1 1257 H5N2
2 1337 H3N4
3 1485 H3N4F
4 1502 H4N4
5 1648 H4N4F
6 1664 H5N4
7 1688 H3N5F
8 1810 H5N4F
9 1851 H4N5F
10 1891 H3N6F
11 1996 H4N5F2
12 2013 H5N5F
13 2028 H6N5
14 2053 H4N6F
15 2175 H6N5F
16 2216 H5N6F
17 2378 H6N6FA. Sroka-Bartnicka et al. / Journal of Pharmace
rom a standard solution (0.046 mg/mL). The captured glycopro-
ein was then deglycosylated for 18, 4, and 2 h using the enzyme
ixture at 37 ◦C under agitation. For each time point tested, two
eplicates were analyzed in duplicate. The comparison of the results
rom each experiment showed no signiﬁcance difference, in terms
f the intensities (Fig. 2a) and ratios (Fig. 2b) of glycan species
etected, when the deglycosylation was performed for a shorter
ime. The intensities (Fig. 2a) have a large relative variation, which
s to be expected when comparing the absolute signal intensities
rom MALDI measurements but this is not reﬂected in the relative
ntensities between different signals within spectra (Fig. 2b).
.4. Speciﬁcity and reproducibility of the bead-based approach
The cross-selectivity of the immunoafﬁnity binders used in this
tudy was assessed by testing different standard protein mixtures.
rotein mix  A, containing both AAT and transferrin, was used as a
ositive control for both proteins, whereas protein mixes B and C,
ot containing the target protein AAT or transferrin respectively,
ere used as negative controls. Representative N-glycan spectra of
he proteins extracted from protein mix  A can be seen in Supporting
nformation Fig. S2 (AAT) and S3 (transferrin).
To avoid contamination by other proteins adsorbed to the plas-
ic, the beads (with the target protein) were transferred to new
ubes before deglycosylation. A comparison between a protein mix
ontaining the target protein (positive control) and a protein mix
ot containing the target protein (negative control) showed that
he signal deriving from nonspeciﬁc binding of other proteins was
ess than 5%, i.e. the intensity from the protein mix  not containing
he target protein was less than 5% of the signal from the protein
ix  containing the target protein, see Supporting information Fig.
2 and S3 .
To assess the reproducibility of the method, standard AAT pro-
ein was analyzed on three different days. Mean values for each
ay were generated from two replicates analyzed in duplicate (Fig.
4). The RSD values from variations between days were found to
e smaller than the variations within a day (Table S1). Thus, the
ethod can be deemed to be reproducible.
Proposed glycan structures, based on the detected m/z values
nd ﬁndings reported in the literature [9,28–30], can be seen in
able 1. The glycans are all detected as sodium adducts, but traces
f potassium adducts can also be seen.
.5. Glycosylation pattern of AAT and transferrin in biological
amples
Representative N-glycan spectra from AAT and transferrin are
hown in Fig. 3. The spectra shown are from experiments with stan-
ard protein solution (Fig. 3a), serum (Fig. 3b), and CSF (Fig. 3c). For
oth AAT and transferrin, the glycan patterns of human serum cor-
espond to the glycan pattern seen for standard protein and they
re in accordance with the literature [28,29]. Thus, the developed
ead-based procedure can be considered accurate. The developed
ead-based method was used to investigate the glycan pattern of
AT in both serum and CSF. Five healthy control samples were used
or serum analysis and three for CSF analysis. Very similar AAT gly-
an patterns were obtained for the different individuals, both in
erum and CSF (Fig. 4). The detected glycan pattern in CSF is how-
ver markedly different from that observed in serum. In serum, the
ajor glycan for all individuals is H5N4, but all test subjects also
ave H5N4F, H6N5, and H6N5F glycans (Table 1, Fig. 4). H6N5 is the
econd largest glycan, followed by H6N5F, and ﬁnally H5N4F.The most striking difference between CSF and serum is the large
umber of different glycans observed in CSF. In serum, four dif-
erent glycans were detected, whereas 15 different glycans were
bserved in CSF. As in serum, the most abundant glycan in CSF is18 2540 H7N6F
H5N4. However, in serum, H5N4 constitutes 60–75% of the total
glycans, whereas in CSF, that proportion is only around 25–50%
(Fig. 4). Two other glycan species, H5N4F and H6N5F, are found in
proportions of around 10% or more and the rest of the detected gly-
cans are in amounts under 10%. Several of the detected glycans are
bisecting (e.g. H3N5F, H4N5F, and H5N6F) and one is a high man-
nose (H5N2) (Table 1, Fig. 4). To the best of our knowledge, this is
the ﬁrst time that the full glycan pattern of AAT in CSF has been
analyzed.
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uggested identity of each glycan signal is displayed in Table 1.
Only one CSF sample was analyzed regarding transferrin. How-
ver, one striking difference compared with AAT would appear to
e the much higher abundance of H3N5F (Fig. 3). A probable rea-
on for this observation is that CSF has been shown to contain
wo transferrin glycoforms, usually referred to as transferrin-1 and
ransferrin-2 [30]. Transferrin-2 has H5N4 as the most abundant
lycan but transferrin-1 has H3N5F as the most abundant, which
ould thus explain the much higher level of H3N5F in transferrin
ompared to AAT.
.6. General discussion
Glycosylation can be viewed as the ﬁnal step in the cell’s
nformation stream − functioning as an on/off switch for protein
unction [31]. Associated with this, defects in protein glycosylation
ave been noted in many diseases including cancer, inﬂammation,
nd autoimmune disorders. We  have developed a method capable
f multiplexed analyses of speciﬁc proteins. The procedure is both
ast and efﬁcient and uses only commercially available materials
nd reagents. Thus, any laboratory with access to a MALDI-TOF-
S  can adapt the described method to investigate changes in
-glycosylation of speciﬁc proteins in complex sample matrixes,
uch as serum and CSF.
Alterations in the glycan pattern of serum proteins have shown
o have potential as biomarkers for both diagnostic purposes and
isease progression [32]. The current method can be used to
evelop panels of particle assays targeting several proteins in which
-glycosylation has been suggested as a possible cancer biomarker,om (a) standard protein, (b) human serum, and (c) human cerebrospinal ﬂuid. The
such as transferrin, haptoglobin, and alpha-fetoprotein for hepato-
cellular cancer. Panels may  also be conceived for autoimmune and
inﬂammatory disorders containing for example alfa-1-acid glyco-
protein, AAT and IgG. The continued development of new afﬁnity
binders of the VHH type, lacking glycans, should beneﬁt the future
development of a wider range of assays.
In this study, the enzymatic release of glycans was achieved
using the enzyme PNGase F in combination with neuraminidase.
All N-linked glycans, except those that contain an 1-3-linked
fucose at the reducing terminal GlcNAc, will be cleaved from the
asparagine residue by PNGase F. Additionally, neuraminidase will
cleave the glycosidic bonds of the terminal sialic acids. Although
changes in the sialic acid content of different proteins have been
reported as potential biomarkers in different types of cancer
(breast, liver, and ovarian) [1], the heterogeneity of the obtained
spectra is increased by the presence of those residues because dif-
ferent sialylation levels of glycans with the same core structure will
give rise to different m/z values. By removing sialic acid residues,
the complexity of the spectra will be reduced and the sensitiv-
ity enhanced, as glycans with a certain core structure will appear
as only one signal [33]. For a number of different diseases, alter-
ations to the core structure or branching of the glycans have been
presented, which can be studied using the present method [1]. If dif-
ferences in sialylation levels are to be measured, then the present
method will probably need to be extended to include permethy-
lation or esteriﬁcation of the released glycans prior to MALDI-MS
analysis.
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Fig. 4. Graphical comparison of the glycosylation pattern of alpha-1-antitrypsin in serum from ﬁve different healthy control individuals (chart inserted in the top right
corner)  and in cerebrospinal ﬂuid from three different healthy control individuals (main chart). Mean values were generated from two replicates analyzed in duplicate. Error
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iars  indicate standard deviations. The relative abundance of glycan signals is calcu
f  the areas from all the glycan signals in that spectrum, given as percent.
Analysis of glycan patterns of proteins from CSF is emerging
s a promising new route for identifying biomarkers for neurode-
enerative diseases. However, most studies so far have focused on
hanges to the total glycosylation pattern in CSF [3,9,34]. A problem
ith analyses of the entire glycoprotein content is that changes in
he concentration of certain proteins may  enhance or obscure the
hanges in glycosylation. Therefore, methods that can be used to
nalyze changes in the glycosylation proﬁle of individual proteins
nown to be of importance for speciﬁc conditions have more poten-
ial when it comes to the diagnosis and monitoring of a disease. For
xample, differences in glycosylation of AAT have been noted in
arkinson’s disease [11] and Alzheimer’s disease [12]. For trans-
errin, two different glycoforms have been identiﬁed, transferrin-1
nd transferrin-2. The ratio between these two different glycoforms
n CSF has been suggested as a possible biomarker for Alzheimer’s
isease [35] and idiopathic normal pressure hydrocephalus [30].
espite the potential for analyzing glycan patterns of speciﬁc pro-
eins as biomarkers in neurological diseases, very few methods
re available. This is probably owing to the more complex glycan
atterns of proteins in CSF compared with those in serum. The
article-based assay described here has the potential to ﬁll this
oid, as it can easily be expanded into an array-type method target-
ng several proteins in which N-glycosylation has been suggested
s a possible biomarker.
. Conclusions
A bead-based afﬁnity puriﬁcation method for proﬁling N-linked
lycan species in serum and CSF has been developed. Streptavidin-
oated magnetic microbeads and VHH based afﬁnity binders were
sed as these confer the possibility of rapidly exchanging the afﬁn-
ty binders or easily using a number of different binders in a single
xperiment. This experimental setup shows a high degree of ﬂex-
bility and a good possibility for automation. This, together withs the area for a speciﬁc glycan signal (for instance m/z = 1810) divided by the sum
the ease of handling, makes this setup extremely promising for
the development of array-type experiments for the simultaneous
analysis of the glycosylation pattern of several target proteins.
Moreover, due to the short time required for the on-beads deg-
lycosylation and since no separation step is required, the entire
procedure is performed in 6 h, allowing for the processing of a
large number of samples in parallel during a single working day. To
our knowledge the method proposed here is the only bead-based
approach not requiring an overnight enzymatic reaction or a glycan
separation step.
The applicability of this method has been exempliﬁed by the
analysis of two  proteins, alpha-1-antitrypsin and transferrin, in
both serum and CSF. These have been suggested as possible N-
linked glycan biomarkers in a number of conditions, such as
cancer, inﬂammation, and neurodegenerative diseases, and exhibit
different glycan proﬁles in the tested sample types. To our knowl-
edge, this is the ﬁrst example of the use of magnetic microbeads
and nonglycosylated immunoafﬁnity binders in combination with
MS analysis for fast and efﬁcient bead-based glycan analysis of
individual proteins from serum and CSF in a protein array-type
experiment.
Acknowledgements
The authors would like to thank Torsten Gordh and Marie
Essermark at the Department of Surgical Sciences, Uppsala Uni-
versity, for providing the CSF samples. We  would also like to
extend our gratitude to Pim Hermans at ThermoFisher in Leiden,
The Netherlands, for providing access to the biotinylated afﬁnity
reagents. Gunnar Thorsén gratefully acknowledges ﬁnancial sup-
port from the Uppsala Technology Centre for Neurodiagnostics and
from the Swedish Research Council (grant no. 2013–4353).
1 utical 
A
t
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[34] S.T. Gizaw, T. Ohashi, M.  Tanaka, H. Hinou, S.I. Nishimura, Biochim. Biophys.32 A. Sroka-Bartnicka et al. / Journal of Pharmace
ppendix A. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.jpba.2016.09.029.
eferences
[1] H.J. An, S.R. Kronewitter, M.L. de Leoz, C.B. Lebrilla, Curr. Opin. Chem. Biol. 13
(2009) 601–607.
[2] E. Marklova, Z. Albahri, M.  Valis, J. Neurol. Sci. 314 (2012) 20–25.
[3] R. Barone, L. Sturiale, A. Palmigiano, M.  Zappia, D. Garozzo, J. Proteomics 75
(2012) 5123–5139.
[4] A. Mackiewicz, K. Mackiewicz, Glycoconjugate J. 12 (1995) 241–247.
[5] C. McCarthy, R. Saldova, M.R. Wormald, P.M. Rudd, N.G. McElvaney, E.P.
Reeves, J. Proteome Res. 13 (2014) 3131–3143.
[6] D.H. Dube, C.R. Bertozzi, Nat. Rev. Drug Discov. 4 (2005) 477–488.
[7] M.  Novokmet, E. Lukic, F. Vuckovic, Z. Ethuric, T. Keser, K. Rajsl, D. Remondini,
G.  Castellani, H. Gasparovic, O. Gornik, G. Lauc, Sci. Rep. 4 (2014) 4347.
[8] O. Gornik, G. Lauc, Dis. Markers 25 (2008) 267–278.
[9] A. Palmigiano, R. Barone, L. Sturiale, C. Sanﬁlippo, R.O. Bua, D.A. Romeo, A.
Messina, M.L. Capuana, T. Maci, F. Le Pira, M.  Zappia, D. Garozzo, J. Proteomics
131 (2016) 29–37.
10] R. Barone, L. Sturiale, A. Fiumara, A. Palmigiano, R.O. Bua, R. Rizzo, M. Zappia,
D.  Garozzo, Autism Res. Off. J. Int. Soc. Autism Res. 9 (2016) 423–428.
11] S. Jesse, S. Lehnert, O. Jahn, L. Parnetti, H. Soininen, S.K. Herukka, P. Steinacker,
S.  Tawﬁk, H. Tumani, C.A. von Arnim, M. Neumann, H.A. Kretzschmar, H.
Kulaksiz, M.  Lenter, J. Wiltfang, B. Ferger, B. Hengerer, M.  Otto, PLoS One 7
(2012) e48783.
12] C. Sihlbom, P. Davidsson, M.  Sjogren, L.O. Wahlund, C.L. Nilsson, Neurochem.
Res. 33 (2008) 1332–1340.
13] A. Hoffmann, M. Nimtz, R. Getzlaff, H.S. Conradt, FEBS Lett. 359 (1995)
164–168.
14] A. Hoffmann, M. Nimtz, U. Wurster, H.S. Conradt, J. Neurochem. 63 (1994)
2185–2196.
15] A. Goyallon, S. Cholet, M.  Chapelle, C. Junot, F. Fenaille, Rapid Commun. Mass
Spectrom. RCM 29 (2015) 461–473.
16] M.  Pabst, F. Altmann, Proteomics 11 (2011) 631–643.
17] M.V. Novotny, W.R. Alley Jr., Curr. Opin. Chem. Biol. 17 (2013) 832–840.
[and Biomedical Analysis 132 (2017) 125–132
18] J. Bones, S. Mittermayr, N. Oı´Donoghue, A. Guttman, P.M. Rudd, Anal. Chem.
82 (2010) 10208–10215.
19] I.M. Lazar, J. Deng, F. Ikenishi, A.C. Lazar, Electrophoresis 36 (2015) 225–237.
20] L.R. Ruhaak, C.A. Koeleman, H.W. Uh, J.C. Stam, D. van Heemst, A.B. Maier, J.J.
Houwing-Duistermaat, P.J. Hensbergen, P.E. Slagboom, A.M. Deelder, M.
Wuhrer, PLoS One 8 (2013) e73082.
21] A.L. Lind, D. Wu,  E. Freyhult, C. Bodolea, T. Ekegren, A. Larsson, M.G.
Gustafsson, L. Katila, J. Bergquist, T. Gordh, U. Landegren, M.
Kamali-Moghaddam, PLoS One 11 (2016) e0149821.
22] E.A. Padlan, Mol. Immunol. 31 (1994) 169–217.
23] C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers,
E.B. Songa, N. Bendahman, R. Hamers, Nature 363 (1993) 446–448.
24] M.  Arbabi Ghahroudi, A. Desmyter, L. Wyns, R. Hamers, S. Muyldermans, FEBS
Lett. 414 (1997) 521–526.
25] M.  Dumoulin, K. Conrath, A. Van Meirhaeghe, F. Meersman, K. Heremans, L.G.
Frenken, S. Muyldermans, L. Wyns, A. Matagne, Protein Sci. Publ. Protein Soc.
11  (2002) 500–515.
26] S.J. van Rensburg, P.A. Berman, F.C. Potocnik, J.J. Taljaard, Metab. Brain Dis. 15
(2000) 243–247.
27] S.J. van Rensburg, P. Berman, F. Potocnik, P. MacGregor, D. Hon, N. de Villiers,
Metab. Brain Dis. 19 (2004) 89–96.
28] E. Landberg, E. Astrom, B. Kagedal, P. Pahlsson, Clin. Chim. Acta Int. J. Clin.
Chem. 414 (2012) 58–64.
29] F. Clerc, K.R. Reiding, B.C. Jansen, G.S. Kammeijer, A. Bondt, M. Wuhrer,
Glycoconjugate J. (2015).
30] S. Futakawa, K. Nara, M.  Miyajima, A. Kuno, H. Ito, H. Kaji, K. Shirotani, T.
Honda, Y. Tohyama, K. Hoshi, Y. Hanzawa, S. Kitazume, R. Imamaki, K.
Furukawa, K. Tasaki, H. Arai, T. Yuasa, M.  Abe, H. Arai, H. Narimatsu, Y.
Hashimoto, Neurobiol. Aging 33 (2012) 1807–1815.
31] E. Maverakis, K. Kim, M.  Shimoda, M.E. Gershwin, F. Patel, R. Wilken, S.
Raychaudhuri, L.R. Ruhaak, C.B. Lebrilla, J. Autoimmun. 57 (2015) 1–13.
32] S.S. Pinho, C.A. Reis, Nat. Rev. Cancer 15 (2015) 540–555.
33] Z. Lin, D.M. Simeone, M.A. Anderson, R.E. Brand, X. Xie, K.A. Shedden, M.T.
Rufﬁn, D.M. Lubman, J. Proteome Res. 10 (2011) 2602–2611.Acta (2016).
35] K. Shirotani, S. Futakawa, K. Nara, K. Hoshi, T. Saito, Y. Tohyama, S. Kitazume,
T.  Yuasa, M.  Miyajima, H. Arai, A. Kuno, H. Narimatsu, Y. Hashimoto, Int. J.
Alzheimer’s Dis. (2011) (2011) 352787.
